摘要
目的探讨丹红注射液对老年慢性心力衰竭患者血胱抑素C(cystatin C,CysC)、同型半胱氨酸(homocysteine,Hcy)及炎症因子水平的影响。方法收集浙江省湖州市吴兴区人民医院内科收治的的老年慢性心力衰竭患者52例,随机分为对照组和实验组,各26例,对照组给予常规治疗,实验组在对照组基础上给予丹红注射液辅助治疗,治疗后,对所有患者的血清CysC、Hcy、核转录因子κB(nuclear transcription factorκB,NF-κB)、白细胞介素-1β(interleukin-1β,IL-1β)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)水平、心功能及不良反应发生率进行检测。结果治疗后,与对照组比较,实验组患者的血清CysC、Hcy水平较低,血清NF-κB、IL-1β及TNF-α水平较低,左心室射血分数(left ventricular ejection fraction,LVEF)、每搏量(stroke volume,SV)较高,差异有统计学意义(P<0.05)。2组患者不良反应的发生率比较差异无统计学意义。结论丹红注射液治疗能够显著降低老年慢性心力衰竭患者血CysC、Hcy及炎症因子水平,减轻炎症反应,改善心功能状态,且安全性较高。
Objective To analyse the effect of Danhong injection on serum levels of cystatin C（ CysC）,homocysteine（ Hcy） and inflammatory factors in elderly patients with chronic heart failure. Methods Fifty-two elderly patients who were diagnosed with chronic heart failure in our hospital were collected. All patients were randomly divided into experimental group and control group,26 cases in each group,the control group were given conventional therapy,the experimental group received Danhong injection adjunctive therapy on the basis of the control group. After treatment,the serum levels of CysC,Hcy,nuclear transcription factor κB（ NF-κB）,interleukin-1β（ IL-1β）,tumor necrosis factor-α（ TNF-α）,heart function and incidence of adverse reactions were detected in all patients. Results After treatment,compared with control group,the serum levels of CysC and Hcy were lower,the serum levels of NF-κB,IL-1β and TNF-α were lower in the experimental group,and the levels of left ventricular ejection fraction（ LVEF） and stroke volume（ SV） were lower in the experimental group,there were significant difference between two groups（ P〈0. 05）. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion The Danhong injection therapy could significantly reduce the serum levels of CysC,Hcy and inflammatory factors in elderly patients with chronic heart failure,reduce the inflammatory reaction,improve the heart function,and have high safety.
出处
《中国生化药物杂志》
CAS
2016年第6期130-132,共3页
Chinese Journal of Biochemical Pharmaceutics
